ArticleClinical and vaccine immunology : CVI2009
Immune responses and protection against experimental challenge after vaccination of bison with Brucella abortus strain RB51 or RB51 overexpressing superoxide dismutase and glycosyltransferase genes.
Article in Clinical and vaccine immunology : CVI, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 53 citations in OpenAlex.
- Immune responses and safety after dart or booster vaccination of bison with Brucella abortus strain RB51.Clinical and vaccine immunology : CVI · 2012Trial
- Immunogenicity of a LipopolysaccharideVaccines · 2025Article
- Epidemiological assessment of bovine brucellosis in Iranian dairy farms: regional Seroprevalence and demographic indicators (2023-2024).Veterinary research communications · 2025Article
- Characterization of the adaptive cellular and humoral immune responses to persistent colonization ofFrontiers in veterinary science · 2024Article
- Comparison of bison and elk susceptibility to experimental challenge withFrontiers in veterinary science · 2024Article
- A review of three decades of use of the cattle brucellosis rough vaccine Brucella abortus RB51: myths and facts.BMC veterinary research · 2023Review
- Effects of concurrent administration of modified live viral vaccines with RB51 on immune responses to RB51.Frontiers in veterinary science · 2023Article
- Design and Characterization of a RecombinantVaccines · 2022Article
- Article
- Bovine Immune Response to Vaccination and Infection with Leptospira borgpetersenii Serovar Hardjo.mSphere · 2021Article
- Immune Responses and Efficacy ofFrontiers in veterinary science · 2021Article
- Registered Influenza Viral Vector BasedFrontiers in cellular and infection microbiology · 2021Article
- Seroprevalence and risk factors of brucellosis and the brucellosis model at the individual level of dairy cattle in the West Bandung District, Indonesia.Veterinary world · 2021Article
- Sustained antigen release polyanhydride-based vaccine platform for immunization against bovine brucellosis.Heliyon · 2019Article
- Development of new generation of vaccines forHeliyon · 2018Review
- Development and trial of vaccines againstJournal of veterinary science · 2017Review
- Protection efficacy of the Brucella abortus ghost vaccine candidate lysed by the N-terminal 24-amino acid fragment (GI24) of the 36-amino acid peptide PMAP-36 (porcine myeloid antimicrobial peptide 36) in murine models.The Journal of veterinary medical science · 2016Article
- Comparison between Immunization Routes of Live Attenuated Salmonella Typhimurium Strains Expressing BCSP31, Omp3b, and SOD of Brucella abortus in Murine Model.Frontiers in microbiology · 2016Article
- Vaccination of Elk (Cervus canadensis) with Brucella abortus Strain RB51 Overexpressing Superoxide Dismutase and Glycosyltransferase Genes Does Not Induce Adequate Protection against Experimental Brucella abortus Challenge.Frontiers in cellular and infection microbiology · 2016Article
- Recent advances in Brucella abortus vaccines.Veterinary research · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vaccination is a tool that could be beneficial in managing the high prevalence of brucellosis in free-ranging bison in Yellowstone National Park. In this study, we characterized immunologic responses and protection against experimental challenge after vaccination of bison with Brucella abortus strain RB51 (RB51) or a recombinant RB51 strain overexpressing superoxide dismutase (sodC) and glycosyltransferase (wboA) genes (RB51+sodC,wboA). Bison were vaccinated with saline only or with 4.6 x 10(10) CFU of RB51 or 7.4 x 10(10) CFU of RB51+sodC,wboA (n = eight animals/treatment). Bison vaccinated with RB51 or RB51+sodC,wboA had greater (P < 0.05) antibody responses, proliferative responses, and production of gamma interferon to RB51 after vaccination than did nonvaccinates. However, bison vaccinated with RB51+sodC,wboA cleared the vaccine strain from draining lymph nodes faster than bison vaccinated with the parental RB51 strain. Immunologic responses of bison vaccinated with RB51+sodC,wboA were similar to responses of bison vaccinated with RB51. Pregnant bison were intraconjunctivally challenged in midgestation with 10(7) CFU of B. abortus strain 2308. Bison vaccinated with RB51, but not RB51+sodC,wboA vaccinates, had greater protection from abortion, fetal/uterine, mammary, or maternal infection than nonvaccinates. Our data suggest that the RB51+sodC,wboA strain is less efficacious as a calfhood vaccine for bison than the parental RB51 strain. Our data also suggest that the RB51 vaccine is a currently available management tool that could be utilized to help reduce brucellosis in free-ranging bison.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.